Zenith Capital logo

Zenith Capital(OTC) ZHCLF

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)+60%
5 Year-99%
1 Year-98%
1 Month+300%
$0.00
+0.00%
+0.00Today
Zenith Capital last closing stock price
MetricPriceDate
Last closeUSD 0.002026-10-12
Zenith Capital stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+300%USD 0.002026-10-05
1 month+300%USD 0.002026-09-10
3 month-97.09%USD 0.062026-07-13
Year to date-89.33%USD 0.022025-12-30
1 year-98.4%USD 0.102025-10-10
3 year-98.67%USD 0.122023-10-13
5 year-99.36%USD 0.252021-10-13
Since inception+60%USD 0.002020-07-10

Zenith Capital Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$9.14M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-3229.61 (Low)

Price

$0.00

Volume

250

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.30

Estimated Earnings Date

Mar 22, 2024

ZHCLF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Zenith Capital

Zenith Capital Corp. is a biotechnology investment company focused on developing bromodomain inhibitors for cancer treatment and other unmet medical needs. The company is advancing its lead compound, ZEN-3694, through clinical trials in collaboration with major pharmaceutical partners.

Products and Services
  • Development of bromodomain inhibitors for cancer treatment
  • Clinical trials for metastatic castration resistant prostate cancer
  • Research collaborations with leading institutions like the National Cancer Institute
Growth Outlook
  • Partnerships with Astellas and Pfizer enhance market potential
  • Ongoing Phase 2 trials could lead to significant breakthroughs
  • Focus on unmet medical needs positions the company for future growth
Financial Highlights
  • Recent quarterly net income of -$2.08 million reflects ongoing R&D investments
  • Trailing twelve months (TTM) P/E ratio of -3.02 indicates potential for future profitability
  • Market capitalization of approximately $23.96 million suggests room for growth
Zenith Capital Corp. operates in a dynamic sector with promising therapeutic developments. The company's strategic collaborations and focus on innovative treatments position it well within the biotechnology landscape. Despite recent financial losses, the ongoing clinical trials and partnerships may pave the way for future success and investor interest.
AI Generated • Sep 22, 2026

Industry

Biotechnology

Headquarters

Calgary, AB T3E 6L1, CA

ZHCLF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

0.00%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

250

Avg. Volume

10.55K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$12.17M

EBITDA

-$2.98M

Operating Cash Flow

$0.00

Capital Expenditure

$0.00

Free Cash Flow

$0.00

Cash & ST Invst.

$0.00

Total Debt

$0.00

Zenith Capital Performance Analysis

Zenith Capital sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-10-31N/A
Q32026-01-31N/A
Q42026-04-30N/A
Q12026-07-31N/A
Zenith Capital sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-10-312.9%
Q32026-01-31-67.7%
Q42026-04-3021.5%
Q12026-07-31-35.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

50,477

N/A

Net Income

-$2.83M

-74.2%

EBITDA

-$940.00K

+4.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$0.00

N/A

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

0.00%

N/A

Return on Invested Capital

0.00%

N/A

Free Cash Flow

$0.00

N/A

Operating Cash Flow

$0.00

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CLCSCell Source, Inc.
$0.49+5.03%
SYGGFSynairgen plc
$0.00+0.00%
PPCBPropanc Biopharma, Inc.
$0.34+0.15%
TELIFTelescope Innovations Corp.
$0.29-0.54%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$89.85-5.79%
NVDANvidia
$214.13-1.43%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$93.67-12.74%
CCCCCC Intelligent Solutions
$7.61-0.26%

Questions About ZHCLF

What is the current price of Zenith Capital?

Zenith Capital is trading at $0.00 per share.

What is the 52-week range for Zenith Capital?

Over the past 52 weeks, Zenith Capital has traded between $0.00 and $0.30.

How much debt does Zenith Capital have?

Zenith Capital total debt is unavailable.

How much cash does Zenith Capital have on hand?

Zenith Capital does not have cash on hand data available.

What is Zenith Capital’s dividend yield?

Zenith Capital does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.